Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 9, 2006, Pages 899-904

  Mielcarek, Marco ^a,b   Georges, George E ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

canine model; denileukin diftitox; graft versus host disease; Hematopoietic cell transplantation

Indexed keywords

DENILEUKIN DIFTITOX; LEUKOCYTE ANTIGEN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; HERPES VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MYELOABLATIVE CONDITIONING; NONHUMAN; PREDICTION; SURVIVAL TIME; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; DOGS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; METHOTREXATE; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; TIME FACTORS; WHOLE-BODY IRRADIATION;

EID: 33747332608     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.05.005     Document Type: Article

References (27)

1. Deeg H.J., Storb R., Appelbaum F.R., et al. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 37 (1984) 62-65
2. Deeg H.J., Storb R., Weiden P.L., et al. Cyclosporin A and methotrexate in canine marrow transplantation. engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 34 (1982) 30-35
3. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
4. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease. initial treatment. Blood 76 (1990) 1464-1472
5. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation. an analysis of clinical risk features and outcome. Blood 75 (1990) 1024-1030
6. Foss F.M. Interleukin-2 fusion toxin. targeted therapy for cutaneous T cell lymphoma. Ann NY Acad Sci 941 (2001) 166-176
7. Taniguchi T., and Minami Y. The IL-2/IL-2 receptor system. a current overview. Cell 73 (1993) 5-8
8. Kagan B.L., Finkelstein A., and Colombini M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc Natl Acad Sci USA 78 (1981) 4950-4954
9. LeMaistre C.F., Saleh M.N., Kuzel T.M., et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91 (1998) 399-405
10. Olsen E., Duvic M., Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2001) 376-388
11. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 1224-1226
12. Shaughnessy P.J., Bachier C., Grimley M., et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 188-193
13. Raff R.F., Storb R., Ladiges W.C., et al. Recognition of target cell determinants associated with DLA-D-locus-encoded antigens by canine cytotoxic lymphocytes. Transplantation 40 (1985) 323-328
14. Storb R., Kolb H.J., Deeg H.J., et al. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplant 1 (1986) 167-177
15. Lee R.S., Kuhr C.S., Sale G.E., et al. FTY720 does not abrogate acute graft-versus-host disease in the DLA-nonidentical unrelated canine model. Transplantation 76 (2003) 1155-1158
16. Wagner J.L., Burnett R.C., DeRose S.A., et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 62 (1996) 876-877
17. Wagner J.L., Works J.D., and Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens 52 (1998) 397-401
18. Yu C., Seidel K., Nash R.A., et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91 (1998) 2581-2587
19. Storb R., Kolb H.J., Graham T.C., et al. Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 42 (1973) 601-609
20. Storb R., Deeg H.J., Raff R., et al. Prevention of graft-versus-host disease. studies in a canine model. Ann NY Acad Sci 770 (1995) 149-164
21. Wagner J.L., and Storb R. Preclinical large animal models for hematopoietic stem cell transplantation. Curr Opin Hematol 3 (1996) 410-415
22. Schwarzinger I., Raff R.F., Flowers M., et al. Recipient-specific donor cytotoxic T-lymphocytes enhance engraftment of unrelated, DLA-nonidentical canine marrow. Bone Marrow Transplant 13 (1994) 303-309
23. reg) block alloreactive host anti-donor T cells in canine mixed hematopoietic chimeras. Blood 106 part 1 (2005) 867a (abstr. 3101)
24. Storb R., and Deeg H.J. Failure of allogeneic canine marrow grafts after total body irradiation. allogeneic "resistance" vs transfusion-induced sensitization. Transplantation 42 (1986) 571-580
25. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 106 (2005) 2903-2911
26. + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 107 (2006) 1717-1723
27. 389IL-2) increases T cell alloreactivity. Blood 104 part 1 (2004) 585a (abstr. 2126)